Dr. David Reardon, MD – Boston, MA
By Zoe Patterson •
Socioeconomic Disparities Associated with MGMT Promoter Methylation Testing for Patients with Glioblastoma
David Reardon, MD, JAMA OncologySocioeconomic Disparities Associated with MGMT Promoter Methylation Testing for Patients with Glioblastoma
David Reardon, MD, JAMA OncologyEffect of Nivolumab vs Bevacizumab in Patients with Recurrent Glioblastoma
David A Reardon, Antonio Omuro, Joachim Baehring, Surasak Phuphanich, Solmaz Sahebjam, JAMA Oncology
